BeyondWest Co-Founder and CMO Robert Hindes, MD, CT

Robert Hindes, MD of Connecticut currently serves as the chief medical officer at Trek Therapeutics, the Cambridge, Mass. based pharmaceutical company he co-founded in 2014. Before establishing Trek Therapeutics, Robert Hindes, MD, spent a decade in various positions with Bristol Myers Squibb (BMS), starting with a role as associate director, and eventually becoming Group Director and Medical Lead for the hepatitis C small molecule development program. In that role, he developed and supervised clinical trials for daclatasvir and asunaprevir, two of the leading hepatitis C drugs at BMS.

Prior to becoming medical lead for the HCV program, Dr. Hindes helped develop and monitor trials for the hepatitis B drug entecavir, which had a successful NDA in 2005. Before co-founding Trek Therapeutics, Dr. Robert Hindes also served as the vice president of clinical development at Pharmasset, Inc., in Princeton, New Jersey.

Supporting the Award-winning Danbury Hospital Praxair Cancer Center

Robert Hindes, MD of CT, is a medical researcher and pharmaceutical consultant with dual board certification in internal medicine and infectious diseases. Prior to becoming a clinical researcher in the pharmaceutical industry, Robert Hindes, MD, was a member of the infectious disease group at Danbury Hospital for over a decade.

As one of the top-ranking medical centers in the Western Connecticut Health Network (WCHN), Danbury Hospital has served Fairfax County for more than 130 years. To continually invest in state-of-the-art medical treatments, Danbury Hospital relies on contributions from fundraisers, such as the WCHN Cancer Golf Tournament.

Scheduled to take place at Rolling Hills Country Club on June 1, 2015, the WCHN Cancer Golf Tournament will support the Praxair Cancer Center at Danbury Hospital, the Diebold Family Center at New Milford Hospital, and the Whittingham Cancer Center at Norwalk Hospital. Over the past 26 years, community members have come together and contributed more than $5 million to programs ranging from early detection and prevention to individualized treatment and survivorship care.

Having become an award-winning institution since its inception over 20 years ago, the Praxair Cancer Center ranks in the top quartile of programs accredited by the American College of Surgeon’s Commission on Cancer.

Protease Inhibitors Explained

The current chief medical officer of Trek Therapeutics in Connecticut, Robert Hindes, MD, has held clinical leadership positions with some of the best-known pharmaceutical companies in the United States, including Bristol Myers Squibb, and Pharmasset. As a former group director at Bristol-Myers Squibb, Robert Hindes, MD, conducted clinical research with protease inhibitors, considered some of the most promising treatment regimens for individuals with Hepatitis C virus (HCV).

Protease inhibitors work by inactivating proteases, enzymes used to break down proteins into smaller chains of amino acids. Many biological proteases involve an active site with a negatively charged analog of the amino acid serine, which functions as a “knife” that cuts an amino acid chain. As such, protease inhibitors often function by deactivating the serine hydroxyl unit.

By preventing proteases from breaking down proteins, protease inhibitors can preserve cellular components and prevent viruses such as HCV from carrying out their normal functions. However, one protease inhibitor is rarely enough to deactivate all known proteases, and the virus commonly develops mutations which are resistant to a specific protease inhibitor. For this reason, antiviral treatment often uses a “cocktail” of multiple HCV drugs from different classes, such as NS5A inhibitors and polymerase inhibitors. In this way, the resistant mutants resulting from protease inhibitors are suppressed by drugs from the other classes of HCV drugs, and the other drugs combine with the protease inhibitors to increase potency against the hepatitis virus. Robert Hindes, MD, is currently evaluating the protease inhibitor Faldaprevir in combination with other HCV drugs.